These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7562399)

  • 1. [Serum 1-methyladenosine and pseudouridine as tumor markers in tumor-bearing mice].
    Ishiwata S; Itoh K; Yamaguchi T; Sasaki S; Ishida N; Mizugaki M
    Yakugaku Zasshi; 1995 Jul; 115(7):523-7. PubMed ID: 7562399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunohistochemical analysis for cancer of the esophagus using monoclonal antibodies specific for modified nucleosides.
    Masuda M; Nishihira T; Itoh K; Mizugaki M; Ishida N; Mori S
    Cancer; 1993 Dec; 72(12):3571-8. PubMed ID: 8252470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular and immunological approach to hematological disease: detection and analysis of intracellular modified nucleosides by flow cytometry].
    Hoshino A; Honda I; Ishimori A; Itoh K; Mizugaki M; Nose M
    Rinsho Byori; 1990 Jul; 38(7):756-64. PubMed ID: 2402080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma.
    Itoh K; Konno T; Sasaki T; Ishiwata S; Ishida N; Misugaki M
    Clin Chim Acta; 1992 Mar; 206(3):181-9. PubMed ID: 1606704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creatinine at the evaluation of urinary 1-methyladenosine and pseudouridine excretion.
    Honda I; Itoh K; Mizugaki M; Sasaki T
    Tohoku J Exp Med; 1999 Jun; 188(2):133-8. PubMed ID: 10526874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic use of anti-modified nucleoside monoclonal antibody.
    Itoh K; Ishiwata S; Ishida N; Mizugaki M
    Tohoku J Exp Med; 1992 Oct; 168(2):329-31. PubMed ID: 1306318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum pseudouridine as a biochemical marker in the development of AKR mouse lymphoma.
    Russo T; Colonna A; Salvatore F; Cimino F; Bridges S; Gurgo C
    Cancer Res; 1984 Jun; 44(6):2567-70. PubMed ID: 6722793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum pseudouridine as a biochemical marker in patients with hepatocellular carcinoma.
    Amuro Y; Nakaoka H; Shimomura S; Fujikura M; Yamamoto T; Tamura S; Hada T; Higashino K
    Clin Chim Acta; 1988 Dec; 178(2):151-8. PubMed ID: 2854011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of urinary nucleosides by high-performance liquid chromatography.
    Liebich HM; Di Stefano C; Wixforth A; Schmid HR
    J Chromatogr A; 1997 Feb; 763(1-2):193-7. PubMed ID: 9129323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of pseudouridine and other nucleosides in human blood serum by high-performance liquid chromatography.
    Colonna A; Russo T; Esposito F; Salvatore F; Cimino F
    Anal Biochem; 1983 Apr; 130(1):19-26. PubMed ID: 6869800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary excretion patterns of modified nucleosides, pseudouridine and 1-methyladenosine, in healthy individuals.
    Itoh K; Aida S; Ishiwata S; Sasaki S; Ishida N; Mizugaki M
    Clin Chim Acta; 1993 Aug; 217(2):221-3. PubMed ID: 8261632
    [No Abstract]   [Full Text] [Related]  

  • 12. [Determination of pseudouridine in serum by high performance liquid chromatography].
    Hu Y; Tang Q; Liu B
    Se Pu; 1997 Jul; 15(4):349-51. PubMed ID: 15739475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between urinary excretion of modified nucleosides and rheumatoid arthritis process.
    Tebib JG; Reynaud C; Cedoz JP; Letroublon MC; Niveleau A
    Br J Rheumatol; 1997 Sep; 36(9):990-5. PubMed ID: 9376997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-Northern Blotting: Detection of Modified RNA Using Gel Separation and Antibodies to Modified Nucleosides.
    Mishima E; Abe T
    Methods Mol Biol; 2019; 1870():179-187. PubMed ID: 30539555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary modified nucleosides as tumor markers in cancer of the urinary organs or female genital tract.
    Koshida K; Harmenberg J; Stendahl U; Wahren B; Borgström E; Helström L; Andersson L
    Urol Res; 1985; 13(5):213-8. PubMed ID: 4060364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight immunosuppressive factors found in elevated amounts in cancer ascitic fluids of mice. 2. 1-Methyladenosine isolated from cancer ascitic fluids enhances Listeria infection in mice.
    Takano S; Sami S; Majima T; Ishida N
    J Immunopharmacol; 1986; 8(1):59-73. PubMed ID: 3711674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA.
    Ishiwata S; Itoh K; Yamaguchi T; Ishida N; Mizugaki M
    Tohoku J Exp Med; 1995 May; 176(1):61-8. PubMed ID: 7482520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control.
    Seidel A; Brunner S; Seidel P; Fritz GI; Herbarth O
    Br J Cancer; 2006 Jun; 94(11):1726-33. PubMed ID: 16685264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrimidine nucleoside, pseudouridine, and modified nucleoside excretion by growing and resting fibroblasts.
    Uziel M; Selkirk JK
    J Cell Physiol; 1979 May; 99(2):217-22. PubMed ID: 457787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of urinary excretion of modified nucleosides in cancer patients using a set of six monoclonal antibodies.
    Reynaud C; Bruno C; Boullanger P; Grange J; Barbesti S; Niveleau A
    Cancer Lett; 1992 Jan; 61(3):255-62. PubMed ID: 1739950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.